$0.29
6.77% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US3724461047
Symbol
GNPX
Sector
Industry

Genprex, Inc. Stock price

$0.29
+0.01 3.55% 1M
-0.87 74.84% 6M
-0.56 65.72% YTD
-2.13 87.94% 1Y
-120.51 99.76% 5Y
-187.71 99.84% 10Y
-187.71 99.84% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.02 6.77%
ISIN
US3724461047
Symbol
GNPX
Sector
Industry

Key metrics

Market capitalization $8.47m
Enterprise Value $5.00m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.82
Free Cash Flow (TTM) Free Cash Flow $-16.00m
Cash position $3.47m
P/E forward negative
Short interest 10.62%

Is Genprex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Genprex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Genprex, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Genprex, Inc.:

Buy
100%

Financial data from Genprex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
21% 21%
-
- Research and Development Expense 11 11
40% 40%
-
-21 -21
32% 32%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -21 -21
32% 32%
-
Net Profit -21 -21
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Genprex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genprex, Inc. Stock News

Neutral
PRNewsWire
11 days ago
AUSTIN, Texas , June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance fr...
Neutral
PRNewsWire
16 days ago
Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas , May 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today annou...
Neutral
PRNewsWire
17 days ago
Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas , May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators presented positive preclinical data and research from studies ...
More Genprex, Inc. News

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Head office United States
CEO Ryan Confer
Employees 15
Founded 2009
Website www.genprex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today